8-K: TuHURA Reports Q3 2025 Results, Advances Clinical Pipeline

TuHURA Biosciences reports Q3 2025 financial results, highlights Phase 3 trial progress, and announces a $50 million ATM facility.

Summary

• Reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
• The Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda for advanced and metastatic Merkel cell carcinoma (MCC) is underway under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).
• The company's Delta Opioid Receptor (DOR) technology was selected for an oral presentation and two poster presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Orlando, Florida on December 6-9, 2025.
• Research and development expenses increased to $4.9 million for the three months ended September 30, 2025, up from $2.9 million for the same period in 2024.
• Net cash outflows from operating activities for the nine months ended September 30, 2025, were ($22.1) million, compared to ($12.1) million for the same period in 2024.
• Total shares outstanding were approximately 51.2 million as of September 30, 2025.
• A $50 Million At-The-Market (ATM) facility was filed in November 2025, allowing the company to sell shares once the S-3 registration statement becomes effective.

Sentiment

Score: 7

Explanation: The filing presents significant clinical progress with a Phase 3 trial underway under an SPA, strong scientific validation for its DOR technology, and clear future milestones. However, increased R&D expenses and cash burn, coupled with the announcement of an ATM facility, indicate a need for capital, which could lead to dilution. The overall sentiment is positive due to clinical and scientific advancements, but tempered by financial considerations.

Positives

• Phase 3 accelerated approval trial for IFx-2.0 in advanced/metastatic MCC is underway with an SPA agreement, which has the potential to satisfy requirements for both accelerated and regular approval without a post-approval confirmatory trial.
• Scientific validation of the Delta Opioid Receptor (DOR) technology with an oral presentation and two poster presentations accepted at the prestigious ASH 2025 Annual Meeting.
• Advancement of the TBS-2025 program with a Phase 2 study protocol submission to the FDA planned for Q4 2025 and trial initiation in Q1 2026.
• Strengthening of the management team with the appointment of Dr. Michael Turner as Vice President of Immunology in November 2025, bringing over 20 years of experience in immunology and oncology.

Negatives

• Research and development expenses increased significantly by 69% to $4.9 million for the three months ended September 30, 2025, compared to $2.9 million in the prior year period.
• Net cash outflows from operating activities for the nine months ended September 30, 2025, increased to ($22.1) million, compared to ($12.1) million for the same period in 2024, indicating a higher cash burn rate.

Risks

• Forward-looking statements are not guarantees of future performance, and actual results or developments may differ materially due to various factors detailed in SEC filings.
• The success of clinical trials for IFx-2.0 (Phase 3) and TBS-2025 (Phase 2) is uncertain and subject to regulatory approvals, trial outcomes, and patient enrollment.
• The ability to raise capital through the $50 million ATM facility is contingent on the S-3 registration statement becoming effective and prevailing market conditions, which could lead to shareholder dilution.
• The company's core mission to overcome primary and acquired resistance to cancer immunotherapy is a significant scientific and clinical challenge.

Future Outlook

The company anticipates several key milestones, including preliminary Phase 1b/2a results for IFx-2.0 in Q2 2026, completion of Phase 3 enrollment for IFx-2.0 in Q4 2026, and topline Phase 3 results in Q1 2027. For TBS-2025, a Phase 2 protocol submission to the FDA is expected in Q4 2025, with trial initiation in Q1 2026. The company also plans to select a lead DOR inhibitor for ADC development in Q1 2026 and expects first proof-of-concept in-vivo results in Q3 2026.

Management Comments

• "TuHURA remains highly focused on the execution of its clinical development programs, including enrollment in our Phase 3 pivotal trial of IFx-2.0 as an adjunctive therapy to pembrolizumab in the first line treatment of patients with advanced or metastatic MCC."
• "This accelerated, registration-directed trial, conducted under an SPA Agreement with the FDA, has the potential, if successful, to satisfy the requirements for both accelerated and regular approval without the need to conduct a post-approval confirmatory trial."
• "In parallel to advancing our late-stage development candidate IFx-2.0, we are working with experts in the treatment of AML to complete the protocol design for our Phase 2 study of TBS-2025, our VISTA inhibiting antibody, in patients with NPM1 mutated AML."
• "We are on track to submit our proposed Phase 2 plan to FDA next month and initiate the Phase 2 randomized study in the first quarter of next year."
• "We were excited to see validation of the scientific merit related to our discovery of the potential role of the DOR expression on Myeloid Derived Suppressor Cells (MDSCs) by being selected by the Joint Program Committees of the ASH 2025 Annual Meeting for an oral presentation."
• "We look forward to presenting our data demonstrating that the DOR is a potential novel target to reprogram the immune suppressing capabilities of MDSCs and tumor-associated macrophages (TAMs)."

Industry Context

TuHURA Biosciences operates in the highly competitive immuno-oncology space, focusing on overcoming primary and acquired resistance to cancer immunotherapy, a critical challenge in cancer treatment. The company's approach with IFx-2.0 targets innate immune activation, while TBS-2025 targets VISTA inhibition, and its DOR technology aims to reprogram immunosuppressive cells like MDSCs and TAMs. These strategies align with broader industry trends seeking to enhance the efficacy of existing checkpoint inhibitors and develop novel mechanisms to address non-responders or those who develop resistance. The acceptance of DOR technology for an oral presentation at ASH 2025 suggests recognition of its scientific merit within the hematology and oncology research community.

Comparison to Industry Standards

• The Phase 3 accelerated approval trial for IFx-2.0 in Merkel Cell Carcinoma (MCC) with an SPA agreement is a significant de-risking factor, as SPA agreements are relatively rare and provide a clear regulatory pathway, similar to how other oncology drugs have achieved accelerated approval (e.g., Keytruda itself in various indications).
• The development of VISTA inhibiting antibodies (like TBS-2025) and Delta Opioid Receptor (DOR) targeting ADCs represents an emerging area in immuno-oncology, aiming to address resistance mechanisms that current therapies, such as PD-1/PD-L1 inhibitors (e.g., Merck's Keytruda, Bristol Myers Squibb's Opdivo), often fail to overcome. This positions TuHURA alongside companies exploring next-generation immune modulators.
• The increase in R&D expenses and cash burn is typical for a Phase 3 clinical-stage biotechnology company, reflecting the high costs associated with late-stage trials and drug development, comparable to peers in similar development stages.

Management Changes

Stakeholder Impact

• Shareholders: Potential for dilution from the $50 million ATM facility; positive impact from clinical trial progress and scientific validation could increase share value; increased R&D expenses and cash burn indicate ongoing investment in pipeline but also financial pressure.
• Patients: Potential for new treatment options for advanced Merkel cell carcinoma and NPM1-mutated AML if clinical trials are successful.
• Employees: Strengthening of the team with new appointments like Dr. Michael Turner.
• Regulatory Authorities (FDA): Ongoing engagement through SPA agreement for IFx-2.0 and planned submission of Phase 2 protocol for TBS-2025.

Next Steps

• Q4 2025: Submit Phase 2 protocol and plan for TBS-2025 to the FDA.
• Q1 2026: Initiate Phase 2 trial of VISTA inhibiting mAb in relapsed or refractory NPM1-mutated AML.
• Q1 2026: Select a lead Delta Opioid Receptor (DOR) inhibitor to conjugate to TBS-2025 for preclinical testing.
• Q2 2026: Anticipate preliminary results from Phase 1b/2a clinical trial of IFx-2.0 in MCC of unknown primary origin (MCCUP).
• Q3 2026: Anticipate first proof of concept in-vivo results from its lead immune modulating ADC.
• Q4 2026: Anticipate completion of enrollment in the randomized, placebo-controlled Phase 3 accelerated approval trial in advanced or metastatic MCC.
• Q1 2027: Anticipate topline results from the Phase 3 accelerated approval trial.
• Sell shares under the $50 Million ATM facility once the S-3 registration statement becomes effective.

Key Dates

Recommendation

The company shows strong clinical progress with a Phase 3 trial under SPA and promising preclinical data for its DOR technology, which are significant positive catalysts. However, the substantial increase in cash burn and the announcement of a $50 million ATM facility suggest upcoming dilution to fund these programs. While the long-term potential is there, the immediate financial implications warrant a "hold" stance until more clarity on the capital raise impact and further clinical data emerges.

Keywords

Immuno-oncology, Cancer immunotherapy, Merkel Cell Carcinoma (MCC), Acute Myeloid Leukemia (AML), IFx-2.0, TBS-2025, Delta Opioid Receptor (DOR), Myeloid Derived Suppressor Cells (MDSCs), Antibody Drug Conjugates (ADCs), Phase 3 clinical trial, FDA Special Protocol Assessment (SPA), Financial results, Biotechnology, Oncology, Drug development